ASCO 2019 – Good results of the anti-BCMA Bispecific T cell engager (BiTE) immunotherapy in relapsed or refractory myeloma patients
ASCO 2019, Chicago – New data of a first-in-human (FIH) phase I dose escalation study evaluating AMG 420, a B-cell maturation antigen (BCMA)-targeting BiTE molecule, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data presented included updated investigational AMG 420 safety and efficacy results in patients with relapsed and/or refractory multiple myeloma (RRMM). BiTE technology is a targeted immuno-oncology platform that is designed to engage…